Evidence map›Paper›PMID 32065057›Full record

ArticleEmerging microbes & infections2020

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes.

Wei Zhang, Rong-Hui Du, Bei Li, Xiao-Shuang Zheng, Xing-Lou Yang, Ben Hu, Yan-Yi Wang, Geng-Fu Xiao, Bing Yan, Zheng-Li Shi and 1 more

4 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Emerging microbes & infections, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 955 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
955citing papers in PubMed, 10 pooled it
46.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04380935 phase2 / phase3unknown statusnot on this map

Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in Indonesia

TypeinterventionalSponsorIndonesia UniversityRan2020 to 2020Enrolled60ConditionsCOVID, Acute Respiratory Distress SyndromeArmsConvalescent plasma, Standard of care
NCT04384380 nacompletednot on this map

A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

TypeinterventionalSponsorTaoyuan General HospitalRan2020 to 2020Enrolled33ConditionsCoronavirus InfectionArmsHydroxychloroquine Sulfate 200 MG [Plaquenil]
NCT04470557 unknown statusnot on this map

The Relationship Between Lab Finding and COVID-19 Severity: Multicenter Study

TypeobservationalSponsorAssiut UniversityRan2020 to 2020Enrolled100ConditionsCOVID-19ArmsD-dimer,CBC.ESR,CRP,, Liver function tests ,serum ferritin and PCR for COVID-19 .
NCT04973462 phase4unknown statusnot on this mapstarted 2021, after this paper: background citation

Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With Coronavirus Disease 2019 (COVID-19)

TypeinterventionalSponsorAin Shams UniversityRan2021 to 2021Enrolled80ConditionsCovid19Armsstandard treatment COVID-19 + Triazavirin
3 · Its place in the literature

Who cites it

955 citing papers in PubMed, 10 syntheses or guidelines pooled it, 1,898 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

895 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Wei ZhangCAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Rong-Hui DuWuhan Pulmonary Hospital, Wuhan, People's Republic of China.
Bei LiCAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Xiao-Shuang ZhengCAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Xing-Lou YangCAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Ben HuCAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Yan-Yi WangCAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Geng-Fu XiaoCAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Bing YanCAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Zheng-Li ShiCAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.ORCID 0000-0001-8089-163X
Peng ZhouCAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.ORCID 0000-0001-9863-4201
Chinese Academy of Sciences · CNWuhan Pulmonary Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In December 2019, a novel coronavirus (2019-nCoV) caused an outbreak in Wuhan, China, and soon spread to other parts of the world. It was believed that 2019-nCoV was transmitted through respiratory tract and then induced pneumonia, thus molecular diagnosis based on oral swabs was used for confirmation of this disease. Likewise, patient will be released upon two times of negative detection from oral swabs. However, many coronaviruses can also be transmitted through oral-fecal route by infecting intestines. Whether 2019-nCoV infected patients also carry virus in other organs like intestine need to be tested. We conducted investigation on patients in a local hospital who were infected with this virus. We found the presence of 2019-nCoV in anal swabs and blood as well, and more anal swab positives than oral swab positives in a later stage of infection, suggesting shedding and thereby transmitted through oral-fecal route. We also showed serology test can improve detection positive rate thus should be used in future epidemiology. Our report provides a cautionary warning that 2019-nCoV may be shed through multiple routes.

Indexed as

Virus SheddingBetacoronavirusChinaCoronavirus InfectionsCOVID-19FecesHumansPneumonia, ViralSARS-CoV-22019-nCoVepidemiologyintestineswabsWuhan pneumonia

Identifiers

PMID32065057
PMCPMC7048229
OpenAlexW3008962515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.